The prognostic value of health-related quality of life for early molecular response in patients with chronic myeloid leukemia: analysis of the GIMEMA-SUSTRENIM trial.
- DOI
- 10.3389/fonc.2025.1645217
- Published
- 2025
- Container
- Frontiers in oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fonc.2025.1645217,
title = {The prognostic value of health-related quality of life for early molecular response in patients with chronic myeloid leukemia: analysis of the GIMEMA-SUSTRENIM trial.},
author = {Efficace F and Cannella L and Capodanno I and Sancetta R and Porcu V and Lunghi M and Biagi A and Castagnetti F and Caocci G and Baldi T and Marasca R and Bonifacio M and Gozzini A and Martino B and Sora F and Westerweel PE and Fazi P and Vignetti M and Pane F and Breccia M},
year = {2025},
journal = {Frontiers in oncology},
doi = {10.3389/fonc.2025.1645217},
url = {https://doi.org/10.3389/fonc.2025.1645217}
}RIS
TY - JOUR TI - The prognostic value of health-related quality of life for early molecular response in patients with chronic myeloid leukemia: analysis of the GIMEMA-SUSTRENIM trial. AU - Efficace F AU - Cannella L AU - Capodanno I AU - Sancetta R AU - Porcu V AU - Lunghi M AU - Biagi A AU - Castagnetti F AU - Caocci G AU - Baldi T AU - Marasca R AU - Bonifacio M AU - Gozzini A AU - Martino B AU - Sora F AU - Westerweel PE AU - Fazi P AU - Vignetti M AU - Pane F AU - Breccia M PY - 2025 JO - Frontiers in oncology DO - 10.3389/fonc.2025.1645217 UR - https://doi.org/10.3389/fonc.2025.1645217 ER -
APA
F, E., L, C., I, C., R, S., V, P., M, L., A, B., F, C., G, C., T, B., R, M., M, B., A, G., B, M., F, S., PE, W., P, F., M, V., F, P., & M, B. (2025). The prognostic value of health-related quality of life for early molecular response in patients with chronic myeloid leukemia: analysis of the GIMEMA-SUSTRENIM trial.. Frontiers in oncology. https://doi.org/10.3389/fonc.2025.1645217
Source records
- pubmed · retrieved 2026-09-25T18:08:54.997Z
- europe-pmc · retrieved 2026-09-25T18:08:54.983Z
- doaj · retrieved 2026-09-25T18:08:54.979Z